Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Exploring Myasthenia Gravis Disease with DLI's Drug Insights, Clinical Trial Management, and Product Development Services | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

10 Oct, 2023, 09:45 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 10, 2023 /PRNewswire/ -- Myasthenia Gravis is a neuromuscular disorder which is quite rate in nature. Epidemiology study suggests that approximately 20 in every 100,000 people are affected with the MG disease.   The prevalence of this ailment may vary among different age groups and genders, with some subgroups having a higher incidence.

Myasthenia Gravis is a chronic neuromuscular disease that typically impacts the communication between our muscles and nerves. It occurs when the immune system mistakenly targets and attacks a specific protein called acetylcholine receptor, which is essential for transmitting nerve signals to muscles. MG complications deteriorate a patient's quality of life.

Timely MG prognosis is crucial to ensure the well being of a patient. This happens only after the disease is diagnosed timely. Proper MG management necessitates effective diagnostic and treatment entities. Industry participants are striving to bring about the much-needed transformation in this vertical. Disease Landscape Insights has been helping them with MG research, treatment gaps identification, product pipeline analysis, drug development, regulatory consulting, clinical trial feasibility analysis, and overall MG clinical trial assessment.

Price and Market Access

It has also been assisting them with the formulation of ideal price and market access strategies along with product portfolio extension plans. This health consultant has also been offering pharma consulting services to the related companies to support them with new product development and post launch strategies.

What are the causes and symptoms of this disorder?

The causes of this ailment may vary based on different parameters. However, MG specialists have listed down a few significant factors leading to the onset of MG complications.  The primary ones are genetics, infections, environmental factors, unhealthy lifestyle habits, and autoimmune reactions.

Major symptoms of this disorder are body ache, fatigue, fever, shortness of breath, digestive issues, swelling, headaches, dizziness, numbness, skin changes, and mental disorders. It is crucial for patients to consult an MG neurologist if the neurological symptoms persist for a long duration.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

Request_Myasthenia Gravis

Detection And Treatment:

MG diagnosis involves a combination of physical examinations and tests. Clinical evaluation, neurological examination, tensilon test, blood tests, electrodiagnostic tests, and certain imaging tests are conducted to identify the occurrence of this ailment.

The Myasthenia Gravis treatment landscape is vast. Treatment plans are made according to the overall health status of a patient. MG medications that are primarily prescribed include cholinesterase inhibitors, monoclonal antibodies, and immunosuppressants.  Apart from that MG therapy like IVIG therapy and physical therapy may also help in some cases.

MG surgery in the form of thymectomy involving the surgical removal of thymus gland (thymectomy) may also be recommended.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

Checkout_Myasthenia Gravis

Final Words:

Myasthenia Gravis primarily affects the body muscles causing movement issues and other symptoms. There are cases where MG can become life-threatening, particularly when it affects the muscles responsible for breathing and swallowing. This is referred to as a myasthenic crisis, and it can result in severe respiratory distress, choking, and difficulty in maintaining adequate oxygen levels. This ailment can be triggered by various factors, including infections, medication changes, or stress. The specific treatment plan for MG is tailored to the individual's needs and the severity of their symptoms. DLI aids in the development of innovative medications that can alleviate the burden of MG symptoms. Its dedication to assisting the patients in terms of drug development is paving the way for more effective therapies. Moreover, DLI's dedication to product development services signifies a holistic approach to addressing the needs of individuals living with MG. The joint efforts between DLI and industry participants promises hope, progress, and a brighter future for the patients affected with this disorder.

Browse Through More Autoimmune Diseases Research Reports.

Related Reports:

Insights and Trends in the Global Landscape of Lung Cancer Services

The symptoms, transmission, and precautions of Monkeypox

The Myths of Pneumonia: Symptoms, Causes, and Prevention Methods

Navigating the Complex Autoimmune Disorder of Lupus

Ringworm Comprehensive Guide: Symptoms, Causes, and Treatment

Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments

When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise.

Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away!

Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately.

Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away!

Chlamydia Disease symptoms, treatment, and market research. Keep up with epidemiology research, FDA and EMA updates, and market entry tactics.

employing our tried-and-true strategy, penetrate the Ovarian Cancer Disease market. Learn to negotiate the regulatory process, discover the key opinion leaders for your product, and establish fair pricing.

Learn about Gastric Cancer Market Strategies, KOL Insights, Regulatory Updates, and Market Intelligence. Make use of our knowledge to get through challenges.

The success of the Breast Cancer market is built on FDA insights, pricing strategies, and a successful market launch. Investigate epidemiology and market intelligence to gain a competitive edge.

Find out more about Prostate Cancer Consulting, FDA-EMA Drugs, Pricing, and Regulatory Insights. Obtain an epidemiology study and market access. Rely on DLI!

FDA-EMA Approved Drugs, Disease Landscape, and Epidemiology Studies: Expert Consulting on Skin Cancer. Pricing Compensation and Market Access.

Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Investigate the epidemiology, prevention, and consulting services for Scrub Typhus. Discover the landscape of diseases, FDA-EMA approved medications, and more.

Discover the market insights, competitive environment, regulatory updates, and epidemiology study for lymphoma. Market entry strategy: Unlock market intelligence.

A Colorectal Cancer market entrance plan can assist you in navigating the competitive environment, getting in touch with important decision-makers, and achieving your regulatory and business objectives. To find out more, call us right away.

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  
isease Landscape Insights LLP  
th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014 
Contact: +44-2038074155 
Asia Office Contact: +917447409162
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services  
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/4328675/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.